 | • レポートコード：QYR2104Z1228 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、中枢神経系（CNS）バイオマーカーのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（安全性バイオマーカー、有効性バイオマーカー、検証バイオマーカー、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・中枢神経系（CNS）バイオマーカーの市場動向 ・企業の競争状況、市場シェア ・中枢神経系（CNS）バイオマーカーの種類別市場規模（安全性バイオマーカー、有効性バイオマーカー、検証バイオマーカー、その他） ・中枢神経系（CNS）バイオマーカーの用途別市場規模（病院、クリニック、その他） ・中枢神経系（CNS）バイオマーカーの北米市場規模2016-2027（アメリカ、カナダ） ・中枢神経系（CNS）バイオマーカーのヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・中枢神経系（CNS）バイオマーカーのアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・中枢神経系（CNS）バイオマーカーの中南米市場規模2016-2027（メキシコ、ブラジル） ・中枢神経系（CNS）バイオマーカーの中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Merck、Takeda Pharmaceutical、Thermo Fisher Scientific、Avacta Group、Diagenic Asa、Banyan Biomarkers、Eli Lilly、Pfizer、Alseres Pharmaceuticals、Acumen pharmaceuticals、EKF Diagnostics、Abiant、Myriad RBM、Aposense） ・結論 |
With extensive ongoing development in personalized medicines and the application of biomarkers in diagnosis, the complexity of the central nervous system paves way for the development of biomarkers to enhance early diagnosis of neurological disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and other neurological conditions.
Market Analysis and Insights: Global Central Nervous System Biomarkers Market
The global Central Nervous System Biomarkers market size is projected to reach US$ 5615.6 million by 2026, from US$ 3743.3 million in 2019, at a CAGR of 5.9% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Central Nervous System Biomarkers market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Central Nervous System Biomarkers market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Central Nervous System Biomarkers market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Central Nervous System Biomarkers market.
Global Central Nervous System Biomarkers Scope and Market Size
Central Nervous System Biomarkers market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Central Nervous System Biomarkers market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Safety Biomarker
Efficacy Biomarker
Validation Biomarker
Other
Segment by Application
Hospitals
Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Merck
Takeda Pharmaceutical
Thermo Fisher Scientific
Avacta Group
Diagenic Asa
Banyan Biomarkers
Eli Lilly
Pfizer
Alseres Pharmaceuticals
Avacta Group
Diagenic Asa
Abiant
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Central Nervous System Biomarkers Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Safety Biomarker
1.2.3 Efficacy Biomarker
1.2.4 Validation Biomarker
1.2.5 Other
1.3 Market by Application
1.3.1 Global Central Nervous System Biomarkers Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Central Nervous System Biomarkers Market Perspective (2016-2027)
2.2 Central Nervous System Biomarkers Growth Trends by Regions
2.2.1 Central Nervous System Biomarkers Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Central Nervous System Biomarkers Historic Market Share by Regions (2016-2021)
2.2.3 Central Nervous System Biomarkers Forecasted Market Size by Regions (2022-2027)
2.3 Central Nervous System Biomarkers Industry Dynamic
2.3.1 Central Nervous System Biomarkers Market Trends
2.3.2 Central Nervous System Biomarkers Market Drivers
2.3.3 Central Nervous System Biomarkers Market Challenges
2.3.4 Central Nervous System Biomarkers Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Central Nervous System Biomarkers Players by Revenue
3.1.1 Global Top Central Nervous System Biomarkers Players by Revenue (2016-2021)
3.1.2 Global Central Nervous System Biomarkers Revenue Market Share by Players (2016-2021)
3.2 Global Central Nervous System Biomarkers Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Central Nervous System Biomarkers Revenue
3.4 Global Central Nervous System Biomarkers Market Concentration Ratio
3.4.1 Global Central Nervous System Biomarkers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Central Nervous System Biomarkers Revenue in 2020
3.5 Central Nervous System Biomarkers Key Players Head office and Area Served
3.6 Key Players Central Nervous System Biomarkers Product Solution and Service
3.7 Date of Enter into Central Nervous System Biomarkers Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Central Nervous System Biomarkers Breakdown Data by Type
4.1 Global Central Nervous System Biomarkers Historic Market Size by Type (2016-2021)
4.2 Global Central Nervous System Biomarkers Forecasted Market Size by Type (2022-2027)
5 Central Nervous System Biomarkers Breakdown Data by Application
5.1 Global Central Nervous System Biomarkers Historic Market Size by Application (2016-2021)
5.2 Global Central Nervous System Biomarkers Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Central Nervous System Biomarkers Market Size (2016-2027)
6.2 North America Central Nervous System Biomarkers Market Size by Type
6.2.1 North America Central Nervous System Biomarkers Market Size by Type (2016-2021)
6.2.2 North America Central Nervous System Biomarkers Market Size by Type (2022-2027)
6.2.3 North America Central Nervous System Biomarkers Market Size by Type (2016-2027)
6.3 North America Central Nervous System Biomarkers Market Size by Application
6.3.1 North America Central Nervous System Biomarkers Market Size by Application (2016-2021)
6.3.2 North America Central Nervous System Biomarkers Market Size by Application (2022-2027)
6.3.3 North America Central Nervous System Biomarkers Market Size by Application (2016-2027)
6.4 North America Central Nervous System Biomarkers Market Size by Country
6.4.1 North America Central Nervous System Biomarkers Market Size by Country (2016-2021)
6.4.2 North America Central Nervous System Biomarkers Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Central Nervous System Biomarkers Market Size (2016-2027)
7.2 Europe Central Nervous System Biomarkers Market Size by Type
7.2.1 Europe Central Nervous System Biomarkers Market Size by Type (2016-2021)
7.2.2 Europe Central Nervous System Biomarkers Market Size by Type (2022-2027)
7.2.3 Europe Central Nervous System Biomarkers Market Size by Type (2016-2027)
7.3 Europe Central Nervous System Biomarkers Market Size by Application
7.3.1 Europe Central Nervous System Biomarkers Market Size by Application (2016-2021)
7.3.2 Europe Central Nervous System Biomarkers Market Size by Application (2022-2027)
7.3.3 Europe Central Nervous System Biomarkers Market Size by Application (2016-2027)
7.4 Europe Central Nervous System Biomarkers Market Size by Country
7.4.1 Europe Central Nervous System Biomarkers Market Size by Country (2016-2021)
7.4.2 Europe Central Nervous System Biomarkers Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Central Nervous System Biomarkers Market Size (2016-2027)
8.2 Asia-Pacific Central Nervous System Biomarkers Market Size by Type
8.2.1 Asia-Pacific Central Nervous System Biomarkers Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Central Nervous System Biomarkers Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Central Nervous System Biomarkers Market Size by Type (2016-2027)
8.3 Asia-Pacific Central Nervous System Biomarkers Market Size by Application
8.3.1 Asia-Pacific Central Nervous System Biomarkers Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Central Nervous System Biomarkers Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Central Nervous System Biomarkers Market Size by Application (2016-2027)
8.4 Asia-Pacific Central Nervous System Biomarkers Market Size by Region
8.4.1 Asia-Pacific Central Nervous System Biomarkers Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Central Nervous System Biomarkers Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Central Nervous System Biomarkers Market Size (2016-2027)
9.2 Latin America Central Nervous System Biomarkers Market Size by Type
9.2.1 Latin America Central Nervous System Biomarkers Market Size by Type (2016-2021)
9.2.2 Latin America Central Nervous System Biomarkers Market Size by Type (2022-2027)
9.2.3 Latin America Central Nervous System Biomarkers Market Size by Type (2016-2027)
9.3 Latin America Central Nervous System Biomarkers Market Size by Application
9.3.1 Latin America Central Nervous System Biomarkers Market Size by Application (2016-2021)
9.3.2 Latin America Central Nervous System Biomarkers Market Size by Application (2022-2027)
9.3.3 Latin America Central Nervous System Biomarkers Market Size by Application (2016-2027)
9.4 Latin America Central Nervous System Biomarkers Market Size by Country
9.4.1 Latin America Central Nervous System Biomarkers Market Size by Country (2016-2021)
9.4.2 Latin America Central Nervous System Biomarkers Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Central Nervous System Biomarkers Market Size (2016-2027)
10.2 Middle East & Africa Central Nervous System Biomarkers Market Size by Type
10.2.1 Middle East & Africa Central Nervous System Biomarkers Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Central Nervous System Biomarkers Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Central Nervous System Biomarkers Market Size by Type (2016-2027)
10.3 Middle East & Africa Central Nervous System Biomarkers Market Size by Application
10.3.1 Middle East & Africa Central Nervous System Biomarkers Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Central Nervous System Biomarkers Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Central Nervous System Biomarkers Market Size by Application (2016-2027)
10.4 Middle East & Africa Central Nervous System Biomarkers Market Size by Country
10.4.1 Middle East & Africa Central Nervous System Biomarkers Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Central Nervous System Biomarkers Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Central Nervous System Biomarkers Introduction
11.1.4 Merck Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.1.5 Merck Recent Development
11.2 Takeda Pharmaceutical
11.2.1 Takeda Pharmaceutical Company Details
11.2.2 Takeda Pharmaceutical Business Overview
11.2.3 Takeda Pharmaceutical Central Nervous System Biomarkers Introduction
11.2.4 Takeda Pharmaceutical Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.2.5 Takeda Pharmaceutical Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Details
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific Central Nervous System Biomarkers Introduction
11.3.4 Thermo Fisher Scientific Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Avacta Group
11.4.1 Avacta Group Company Details
11.4.2 Avacta Group Business Overview
11.4.3 Avacta Group Central Nervous System Biomarkers Introduction
11.4.4 Avacta Group Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.4.5 Avacta Group Recent Development
11.5 Diagenic Asa
11.5.1 Diagenic Asa Company Details
11.5.2 Diagenic Asa Business Overview
11.5.3 Diagenic Asa Central Nervous System Biomarkers Introduction
11.5.4 Diagenic Asa Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.5.5 Diagenic Asa Recent Development
11.6 Banyan Biomarkers
11.6.1 Banyan Biomarkers Company Details
11.6.2 Banyan Biomarkers Business Overview
11.6.3 Banyan Biomarkers Central Nervous System Biomarkers Introduction
11.6.4 Banyan Biomarkers Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.6.5 Banyan Biomarkers Recent Development
11.7 Eli Lilly
11.7.1 Eli Lilly Company Details
11.7.2 Eli Lilly Business Overview
11.7.3 Eli Lilly Central Nervous System Biomarkers Introduction
11.7.4 Eli Lilly Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.7.5 Eli Lilly Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Central Nervous System Biomarkers Introduction
11.8.4 Pfizer Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.8.5 Pfizer Recent Development
11.9 Alseres Pharmaceuticals
11.9.1 Alseres Pharmaceuticals Company Details
11.9.2 Alseres Pharmaceuticals Business Overview
11.9.3 Alseres Pharmaceuticals Central Nervous System Biomarkers Introduction
11.9.4 Alseres Pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.9.5 Alseres Pharmaceuticals Recent Development
11.10 Acumen pharmaceuticals
11.10.1 Acumen pharmaceuticals Company Details
11.10.2 Acumen pharmaceuticals Business Overview
11.10.3 Acumen pharmaceuticals Central Nervous System Biomarkers Introduction
11.10.4 Acumen pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.10.5 Acumen pharmaceuticals Recent Development
11.11 EKF Diagnostics
11.11.1 EKF Diagnostics Company Details
11.11.2 EKF Diagnostics Business Overview
11.11.3 EKF Diagnostics Central Nervous System Biomarkers Introduction
11.11.4 EKF Diagnostics Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.11.5 EKF Diagnostics Recent Development
11.12 Abiant
11.12.1 Abiant Company Details
11.12.2 Abiant Business Overview
11.12.3 Abiant Central Nervous System Biomarkers Introduction
11.12.4 Abiant Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.12.5 Abiant Recent Development
11.13 Myriad RBM
11.13.1 Myriad RBM Company Details
11.13.2 Myriad RBM Business Overview
11.13.3 Myriad RBM Central Nervous System Biomarkers Introduction
11.13.4 Myriad RBM Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.13.5 Myriad RBM Recent Development
11.14 Aposense
11.14.1 Aposense Company Details
11.14.2 Aposense Business Overview
11.14.3 Aposense Central Nervous System Biomarkers Introduction
11.14.4 Aposense Revenue in Central Nervous System Biomarkers Business (2016-2021)
11.14.5 Aposense Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Central Nervous System Biomarkers Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Safety Biomarker
Table 3. Key Players of Efficacy Biomarker
Table 4. Key Players of Validation Biomarker
Table 5. Key Players of Other
Table 6. Global Central Nervous System Biomarkers Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Central Nervous System Biomarkers Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Central Nervous System Biomarkers Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Central Nervous System Biomarkers Market Share by Regions (2016-2021)
Table 10. Global Central Nervous System Biomarkers Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Central Nervous System Biomarkers Market Share by Regions (2022-2027)
Table 12. Central Nervous System Biomarkers Market Trends
Table 13. Central Nervous System Biomarkers Market Drivers
Table 14. Central Nervous System Biomarkers Market Challenges
Table 15. Central Nervous System Biomarkers Market Restraints
Table 16. Global Central Nervous System Biomarkers Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Central Nervous System Biomarkers Market Share by Players (2016-2021)
Table 18. Global Top Central Nervous System Biomarkers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Central Nervous System Biomarkers as of 2020)
Table 19. Ranking of Global Top Central Nervous System Biomarkers Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Central Nervous System Biomarkers Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Central Nervous System Biomarkers Product Solution and Service
Table 23. Date of Enter into Central Nervous System Biomarkers Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Central Nervous System Biomarkers Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Central Nervous System Biomarkers Revenue Market Share by Type (2016-2021)
Table 27. Global Central Nervous System Biomarkers Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Central Nervous System Biomarkers Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Central Nervous System Biomarkers Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Central Nervous System Biomarkers Revenue Market Share by Application (2016-2021)
Table 31. Global Central Nervous System Biomarkers Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Central Nervous System Biomarkers Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Central Nervous System Biomarkers Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Central Nervous System Biomarkers Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Central Nervous System Biomarkers Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Central Nervous System Biomarkers Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Central Nervous System Biomarkers Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Central Nervous System Biomarkers Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Central Nervous System Biomarkers Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Central Nervous System Biomarkers Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Central Nervous System Biomarkers Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Central Nervous System Biomarkers Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Central Nervous System Biomarkers Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Central Nervous System Biomarkers Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Central Nervous System Biomarkers Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Central Nervous System Biomarkers Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Central Nervous System Biomarkers Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Central Nervous System Biomarkers Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Central Nervous System Biomarkers Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Central Nervous System Biomarkers Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Central Nervous System Biomarkers Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Central Nervous System Biomarkers Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Central Nervous System Biomarkers Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Central Nervous System Biomarkers Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Central Nervous System Biomarkers Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Central Nervous System Biomarkers Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Central Nervous System Biomarkers Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Central Nervous System Biomarkers Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Central Nervous System Biomarkers Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Central Nervous System Biomarkers Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Central Nervous System Biomarkers Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Central Nervous System Biomarkers Market Size by Country (2022-2027) & (US$ Million)
Table 63. Merck Company Details
Table 64. Merck Business Overview
Table 65. Merck Central Nervous System Biomarkers Product
Table 66. Merck Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 67. Merck Recent Development
Table 68. Takeda Pharmaceutical Company Details
Table 69. Takeda Pharmaceutical Business Overview
Table 70. Takeda Pharmaceutical Central Nervous System Biomarkers Product
Table 71. Takeda Pharmaceutical Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 72. Takeda Pharmaceutical Recent Development
Table 73. Thermo Fisher Scientific Company Details
Table 74. Thermo Fisher Scientific Business Overview
Table 75. Thermo Fisher Scientific Central Nervous System Biomarkers Product
Table 76. Thermo Fisher Scientific Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 77. Thermo Fisher Scientific Recent Development
Table 78. Avacta Group Company Details
Table 79. Avacta Group Business Overview
Table 80. Avacta Group Central Nervous System Biomarkers Product
Table 81. Avacta Group Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 82. Avacta Group Recent Development
Table 83. Diagenic Asa Company Details
Table 84. Diagenic Asa Business Overview
Table 85. Diagenic Asa Central Nervous System Biomarkers Product
Table 86. Diagenic Asa Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 87. Diagenic Asa Recent Development
Table 88. Banyan Biomarkers Company Details
Table 89. Banyan Biomarkers Business Overview
Table 90. Banyan Biomarkers Central Nervous System Biomarkers Product
Table 91. Banyan Biomarkers Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 92. Banyan Biomarkers Recent Development
Table 93. Eli Lilly Company Details
Table 94. Eli Lilly Business Overview
Table 95. Eli Lilly Central Nervous System Biomarkers Product
Table 96. Eli Lilly Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 97. Eli Lilly Recent Development
Table 98. Pfizer Company Details
Table 99. Pfizer Business Overview
Table 100. Pfizer Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 101. Pfizer Recent Development
Table 102. Alseres Pharmaceuticals Company Details
Table 103. Alseres Pharmaceuticals Business Overview
Table 104. Alseres Pharmaceuticals Central Nervous System Biomarkers Product
Table 105. Alseres Pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 106. Alseres Pharmaceuticals Recent Development
Table 107. Acumen pharmaceuticals Company Details
Table 108. Acumen pharmaceuticals Business Overview
Table 109. Acumen pharmaceuticals Central Nervous System Biomarkers Product
Table 110. Acumen pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 111. Acumen pharmaceuticals Recent Development
Table 112. EKF Diagnostics Company Details
Table 113. EKF Diagnostics Business Overview
Table 114. EKF Diagnostics Central Nervous System Biomarkers Product
Table 115. EKF Diagnostics Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 116. EKF Diagnostics Recent Development
Table 117. Abiant Company Details
Table 118. Abiant Business Overview
Table 119. Abiant Central Nervous System Biomarkers Product
Table 120. Abiant Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 121. Abiant Recent Development
Table 122. Myriad RBM Company Details
Table 123. Myriad RBM Business Overview
Table 124. Myriad RBM Central Nervous System Biomarkers Product
Table 125. Myriad RBM Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 126. Myriad RBM Recent Development
Table 127. Aposense Company Details
Table 128. Aposense Business Overview
Table 129. Aposense Central Nervous System Biomarkers Product
Table 130. Aposense Revenue in Central Nervous System Biomarkers Business (2016-2021) & (US$ Million)
Table 131. Aposense Recent Development
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Central Nervous System Biomarkers Market Share by Type: 2020 VS 2027
Figure 2. Safety Biomarker Features
Figure 3. Efficacy Biomarker Features
Figure 4. Validation Biomarker Features
Figure 5. Other Features
Figure 6. Global Central Nervous System Biomarkers Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Central Nervous System Biomarkers Report Years Considered
Figure 11. Global Central Nervous System Biomarkers Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Central Nervous System Biomarkers Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Central Nervous System Biomarkers Market Share by Regions: 2020 VS 2027
Figure 14. Global Central Nervous System Biomarkers Market Share by Regions (2022-2027)
Figure 15. Global Central Nervous System Biomarkers Market Share by Players in 2020
Figure 16. Global Top Central Nervous System Biomarkers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Central Nervous System Biomarkers as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Central Nervous System Biomarkers Revenue in 2020
Figure 18. Global Central Nervous System Biomarkers Revenue Market Share by Type (2016-2021)
Figure 19. Global Central Nervous System Biomarkers Revenue Market Share by Type (2022-2027)
Figure 20. North America Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Central Nervous System Biomarkers Market Share by Type (2016-2027)
Figure 22. North America Central Nervous System Biomarkers Market Share by Application (2016-2027)
Figure 23. North America Central Nervous System Biomarkers Market Share by Country (2016-2027)
Figure 24. United States Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Central Nervous System Biomarkers Market Share by Type (2016-2027)
Figure 28. Europe Central Nervous System Biomarkers Market Share by Application (2016-2027)
Figure 29. Europe Central Nervous System Biomarkers Market Share by Country (2016-2027)
Figure 30. Germany Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Central Nervous System Biomarkers Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Central Nervous System Biomarkers Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Central Nervous System Biomarkers Market Share by Region (2016-2027)
Figure 40. China Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Central Nervous System Biomarkers Market Share by Type (2016-2027)
Figure 48. Latin America Central Nervous System Biomarkers Market Share by Application (2016-2027)
Figure 49. Latin America Central Nervous System Biomarkers Market Share by Country (2016-2027)
Figure 50. Mexico Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Central Nervous System Biomarkers Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Central Nervous System Biomarkers Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Central Nervous System Biomarkers Market Share by Country (2016-2027)
Figure 56. Turkey Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Central Nervous System Biomarkers Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Merck Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 60. Takeda Pharmaceutical Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 61. Thermo Fisher Scientific Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 62. Avacta Group Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 63. Diagenic Asa Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 64. Banyan Biomarkers Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 65. Eli Lilly Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 66. Pfizer Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 67. Alseres Pharmaceuticals Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 68. Acumen pharmaceuticals Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 69. EKF Diagnostics Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 70. Abiant Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 71. Myriad RBM Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 72. Aposense Revenue Growth Rate in Central Nervous System Biomarkers Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
世界の中枢神経系（CNS）障害治療市場規模・現状・予測（2021年-2027年） Central Nervous System (CNS) disorders are also called as neurological and psychiatric disorders. CNS disorders can affect either the brain or spinal cord, or both. Depression is the dominated market of CNS Disorders Therapeutics Market Analysis and Insights: Global Central Nervous System Disorders …- 世界の中枢神経系（CNS）治療市場規模・現状・予測（2021年-2027年） The central nervous system (CNS) is the part of thenervous system consisting of the brain and spinal cord. In this report, we study the drugs for central nervous system disease. Market Analysis and Insights: Global Central Nervous System Treatment Market The global Central Nervous System Treatment m…
- 世界の中枢神経系（CNS）治療市場規模・現状・予測（2021年-2027年） The central nervous system (CNS) is the part of thenervous system consisting of the brain and spinal cord. In this report, we study the drugs for central nervous system disease. Market Analysis and Insights: Global Central Nervous System Therapeutic Market The global Central Nervous System Therapeut…
- 世界の中枢神経系（CNS）治療市場規模・現状・予測（2021年-2027年） A central nervous system (CNS) disease can affect either the brain or the spinal cord which leads to neurological or psychiatric disorders. Advancements in diagnostics, therapeutics and drug discovery techniques will further trigger the growth of central nervous system therapeutic market. Market Ana…
- 世界の診断バイオマーカー市場規模・現状・予測（2021年-2027年） Biomarkers have its property and the biological functions or molecules that are detected in various vitals of the body such as blood and other fluids. Further, they are then measured in those parts. They may indicate either normal or diseased processes in the body. Biomarkers are used in various pur…